Overview

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

Status:
Completed
Trial end date:
2019-04-05
Target enrollment:
Participant gender:
Summary
The overall goal of this project is to develop initial human data on effects of novel compounds on safety (interactions with oxycodone) and efficacy (subjective response to oxycodone) in non-treatment seeking opioid use disorder subjects. The compound to be studied will be the 5-HT2CR agonist lorcaserin. There are no known or reported adverse interactions between lorcaserin and oxycodone or other opioids.
Phase:
Phase 1
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
National Institute on Drug Abuse (NIDA)